BACKGROUND: Outcomes in patients with chronic myeloid leukemia in blast phase (CML-BP) are historically dismal. Herein, the authors sought to analyze the characteristics, prognostic factors, and survival outcomes in patients with CML-BP in the tyrosine kinase inhibitor (TKI) era. METHODS: A total of 477 patients with CML-BP were treated with a TKI at some point during the course of their CML. Cox proportional hazard models identified characteristics that were predictive of survival. Overall survival and failure-free survival were assessed. Optimal cutoff points for specific parameters were identified using classification and regression tree (CART) analysis. RESULTS: The median age of the patients was 53 years (range, 16-84 years) and 64% were male. Approximately 80% of patients initially were diagnosed in the chronic phase of CML at a median of 41 months (range, 0.7-298 months) before transformation to CML-BP. De novo CML-BP occurred in 71 patients. Approximately 72% of patients received TKI therapy before CML-BP. The initial therapy for CML-BP included a TKI alone (35%), a TKI with chemotherapy (46%), and non-TKI therapies (19%). The median overall survival was 12 months and the median failure-free survival was 5 months. In multivariate analysis, myeloid immunophenotype, prior TKI, age 58 years, lactate dehydrogenase level 1227 IU/L, platelet count < 102 K/lL, no history of stem cell transplantation, transition to BP from chronic phase/accelerated phase, and the presence of chromosome 15 aberrations predicted for a significantly increased risk of death. Achievement of major hematologic response and/or complete cytogenetic response to first-line treatment was found to be predictive of better survival. The combination of a TKI with intensive chemotherapy followed by stem cell transplantation appeared to confer the best outcome. CONCLUSIONS: Patients with CML-BP continue to pose a therapeutic challenge, have dismal outcomes, and require newer treatment approaches. Cancer 2017;123:4391-402.
INTRODUCTION
With the widespread use of tyrosine kinase inhibitors (TKIs) for the treatment of patients with chronic myeloid leukemia (CML), the risk of transformation to blast phase (BP) has markedly decreased. However, a significant minority of patients will have their disease transform to BP; this occurs less frequently in patients treated with second-generation TKIs as their initial therapy. 1 The median survival in patients with CML-BP is < 12 months. [2] [3] [4] [5] The pathobiology of CML-BP involves multiple intermingling pathways with genetic and epigenetic aberrations involved in transformation, but to our knowledge is not fully understood. 6 Although the poor prognosis of patients with CML-BP is well recognized, to our knowledge the predictive prognostic features in the era of TKIs have been addressed only briefly. One study with 51 patients with CML-BP (only a minority of whom were treated with a TKI) suggested that a low platelet count and age >60 years were predictive of poor survival. 2 Generally, patients with CML-BP are treated with a TKI combined with intensive chemotherapy followed by allogenic stem cell transplantation (SCT); survival has improved with combined modality treatment compared with that observed with use of a TKI alone. [7] [8] [9] To the best of our knowledge, the current study is the largest analysis of CML-BP to date, describing the clinical characteristics, prognostic factors, survival outcomes, and treatments for patients with CML-BP who received a TKI at some point during the course of CML.
MATERIALS AND METHODS
A total of 477 patients with CML-BP (defined as 30% blasts in the peripheral blood and/or bone marrow or extramedullary disease [EMD] ) who were seen at The University of Texas MD Anderson Cancer Center from 1997 to 2016 were included in the current analysis. A retrospective chart review protocol was approved by the Institutional Review Board and a waiver of informed consent was obtained. Response to treatment was assessed after initial treatment for CML-BP as defined previously. 10 Major hematologic response (MHR) encompasses both complete hematologic response and no evidence of leukemia. Definitions of cytogenetic and molecular response were as previously described. 11 The pattern of clonal evolution was classified as previously described. 12 Only patients with available information regarding treatment and response and who received frontline therapy for CML-BP were included in the final analysis. Overall survival (OS) was assessed from the date of diagnosis of BP until death or the date of last follow-up. Failure-free survival (FFS) was assessed from the time of the initiation of first-line treatment of CML-BP to the date of first disease recurrence, switch to second-line therapy, death, or last follow-up.
Statistical Analysis
Univariate and multivariate Cox proportional hazard models were performed to identify specific characteristics of CML-BP that are predictive of survival outcomes. Variables with a P value .25 in the univariate analysis were entered into a multivariate model. The median survival and survival probabilities were analyzed using the Kaplan-Meier method and differences were calculated with the log-rank test. We used classification and regression tree (CART) analysis to identify the optimal cutoff points for specific parameters associated with survival; we subsequently identified prognostic factors that could independently predict survival in patients with CML-BP. A P value < .05 was considered to be statistically significant. Statistical analyses were performed using STATA/SE statistical software (version 14.1; StataCorp LLC, College Station, Texas).
RESULTS

Patients and Disease Characteristics
A total of 477 patients with CML-BP who were treated with a TKI at some point during the course of their disease were included in this analysis. Among these patients, 343 (72%) were treated with a TKI before developing CML-BP and 195 of these individuals (57%) were evaluable for response. Response to prior TKI therapy was complete hematologic response in 97% of patients, complete cytogenetic response (CCyR) in 31% of patients, and major molecular response (MMR) in 11% of patients. The majority of the patients (381 patients; 80%) were in the chronic phase of CML (CML-CP) at the time of the initial CML diagnosis, with a median time from initial diagnosis of CML-CP to BP of 41 months (range, 0.7-298 months). A total of 25 patients (5%) were in the accelerated phase of CML (CML-AP) at the time of the initial diagnosis of CML; their median time from the initial diagnosis of CML-AP to BP was 14 months (range, 0.4-160 months). De novo CML-BP was observed in 71 patients (15%). The types of first-line treatment received by patients in CP and AP, respectively, at the time of the initial diagnosis of CML included interferon-based treatment (37% and 16%), imatinib (26% and 48%), miscellaneous treatments (21% and 16%), dasatinib (6% and 4%), chemotherapy alone (5%), and nilotinib (5% and 16%). For patients in CP who initially were treated with imatinib (99 patients) and had their disease transform to BP, 24 received imatinib as part of their initial therapy for CML-BP, whereas 31 patients received dasatinib, 7 patients received nilotinib, 3 patients received ponatinib, and 2 patients received bosutinib.
Patient and disease characteristics at the time of diagnosis of CML-BP are summarized in Table 1 and in Supporting Information Figure 1 . Overall, the median age of the patients was 53 years (range, 16-84 years), 64% of the patients were male, and 65% of the patients were Caucasians. Extramedullary BP was identified in 128 patients (27%; isolated extramedullary BP was identified in 50 patients [39%]). The distribution of patients according to immunophenotype was myeloid in 67% of patients, lymphoid in 28% of patients, mixed lineage in 4% of patients, and megakaryocytic in 0.5% of patients; the undifferentiated immunophenotype occurred less frequently (0.5% of patients) and the immunophenotype was unknown in 19 patients. The most common transcript type was e13a2 in 41% of patients. Distribution of Abelson murine leukemia viral oncogene homolog (ABL) mutations is shown in Table 1 . Approximately 43% of patients (200 patients) had clonal evolution, 18% of whom (85 patients) were in group 1 (trisomy 8, -Y aberration, and extra Philadelphia chromosome), 14% (68 patients) were in group 2 (iso17, chromosome 3 aberration, and -7/-7p), and 10% (47 patients) were an overlap of both groups; 55% (263 patients) did not belong to either group (Table 2 ) (see Supporting Information Fig. 2 ). Approximately 6% of the patients had a variant Philadelphia chromosome. Using CART analysis, we identified the optimal cutoff values for different continuous variables that correlated with survival outcomes, including age (<58 years vs 58 years), hemoglobin (<13 g/dL vs 13 g/dL), platelet count (<102 K/mL vs 102 K/mL), bone marrow blast percentage (<5% vs 5%), and serum lactate dehydrogenase (LDH) level (<1227 IU/L vs 1227 IU/L). Abbreviations: CML-BP, chronic myeloid leukemia in blast phase; Del, deletion; Ph1, Philadelphia chromosome positive.
Type of Treatments and Response to First-Line Therapy in Patients With CML-BP
We then analyzed the initial treatment for CML-BP and response to therapy in 426 patients (89%) for whom information was available (Table 3) . Treatment modalities were divided into TKI alone (149 patients; 35%), TKI plus chemotherapy (195 patients; 46%), and non-TKI-based therapies (82 patients; 19%). Non-TKI-based therapies included cytosine arabinoside-based regimens (non-hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone [hyper-CVAD]; 23 patients), troxacitabine (13 patients), hyper-CVAD (6 patients), omacetaxine (6 patients), gemtuzumab-based therapy (4 patients), and miscellaneous therapies (including investigational) (30 patients). The distribution of patients according to the type of TKI was as follows: imatinib in 189 patients (55%), dasatinib in 110 patients (32%), nilotinib in 26 patients (8%), ponatinib in 15 patients (4%), and bosutinib in 5 patients (1%). The overall rates of MHR, CCyR, and MMR were 50%, 21%, and 12%, respectively. Patients treated with a combination of TKI with chemotherapy were found to have a significantly higher MHR compared with patients receiving other modalities (P 5 .0001). Similarly, rates of CCyR and MMR were higher among patients treated with a TKI combined with chemotherapy. Patients treated with dasatinib or ponatinib had a numerical trend toward better response rates. MHR was not found to be significantly higher with dasatinib compared with imatinib (P 5 .08). Because few patients were treated with other TKIs, we were unable to compare dasatinib with other TKIs. Of the 149 patients who were treated with TKIs alone as a first-line treatment for CML-BP, 80 patients (54%) were treated with imatinib and of these patients, 76 (95%) developed disease progression. A total of 104 patients (22%) underwent SCT at some point after the diagnosis of CML-BP. The percentage of patients who underwent SCT was higher among those treated with TKI-based combinations (21%) compared with those treated with a TKI alone or non-TKI therapy (3% and 10%, respectively). A total of 25 patients (35%) with de novo CML-BP underwent SCT compared with 79 (19%) of those who had transformed from CML-CP/AP. At the time of SCT, 12 patients remained in BP, 79 patients (76%) were in MHR, and 45 patients (43%) were in CCyR. The percentages of patients who underwent SCT according to the type of response achieved were 33% versus 16% for MHR versus no MHR, 40% versus 26% for CCyR versus no CCyR, and 43% versus 15% for MMR versus no MMR. Additional reasons for not undergoing SCT in 373 patients were disease progression/disease-related complications in 46% of patients, unknown and/or lost to follow-up in 50% of patients, and non-CML-associated comorbidities in 4% of patients. It is interesting to note that 56 of the patients who underwent SCT (54%) required 2 therapies for CML-BP to be able to proceed to SCT. Overall, 56 patients (54%) required second or subsequent therapies to proceed to SCT.
Prognostic Factors and Survival Outcomes in Patients With CML-BP
The median follow-up was 11.5 months (range, 0-195 months). The median OS was 12 months with a rate of death of 79%; the median FFS was 5 months, with 87% of patients failing first-line treatment (Figs. 1A and 1B) . We then analyzed the impact of various patient characteristics at the time of CML-BP on OS and FFS. Patients with de novo BP had a longer OS compared with patients who transformed from CML-CP/CML-AP (P<.0001) (Fig. 1C) . As shown in Figure 1D , OS has progressively improved from 2000 (ie, the advent of imatinib) to the present date. Patients with lymphoid immunophenotype and patients who were not treated with a TKI before transformation to CML-BP were found to have a longer survival compared with patients with myeloid significant correlation with inferior survival outcome were hemoglobin <13 g/dL, male sex, bone marrow blast percentage at the time of BP transformation of 5% (compared with EMD only), a platelet count <102 3 10 9 /L, lack of isolated EMD, and a higher number of prior TKIs and no SCT after CML-BP. OS 
We then examined the impact of the type of treatment and responses achieved in patients with CML-BP. Patients treated with the combination of a TKI with chemotherapy were found to have superior outcomes compared with patients treated with a TKI alone (P 5 .005) ( Fig. 2A) or with non-TKI-based treatments. This correlates with a more frequent use of the combination of TKI with chemotherapy (74% of patients treated between 2010-2016 compared with 36% of patients treated between 2000-2004). Because of the small numbers of patients treated with some individual TKI, no firm conclusions could be drawn regarding the impact of individual TKIs, but there was a suggestion of better survival for patients treated with dasatinib compared with imatinib (P 5 .06) (Fig. 2B ). Other TKI cohorts had too few patients to evaluate. Patients who underwent SCT after their initial treatment for CML-BP had a significantly longer survival compared with patients who did not undergo SCT after their initial therapy (Fig. 2C) . Moreover, patients who achieved MHR or CCyR or MMR after initial BP treatment were found to have better survival outcomes (see Supporting Information Figs. 3A-3C).
We also analyzed the impact of patient characteristics on FFS. Patients with myeloid immunophenotype, prior TKI therapy, age 58 years, and an LDH level marrow blast percentage 5%, a platelet count <102 3 10 9 /L, lack of isolated EMD, or who had not undergone SCT after CML-BP were found to have a significantly inferior FFS. Patients who achieved MHR or CCyR or MMR after initial BP treatment had a significantly longer FFS (P<.0001) (see Supporting Information Figs. 3D-3F) . Furthermore, patients treated with the combination of a TKI with chemotherapy had superior FFS compared with patients treated with a TKI alone (P<.001) (Fig. 3A) or with non-TKI-based treatments. Similar to OS, there was a trend toward longer FFS with dasatinib compared with imatinib (P 5 .06) (Fig. 3B) . Patients who underwent SCT after their initial treatment of CML-BP had a significantly longer FFS compared with those patients who did not undergo SCT after their initial therapy (Fig. 3C) .
First-line treatment for patients with de novo CML-BP included TKI alone (24 patients; 34%), TKI plus chemotherapy (41 patients; 58%), non-TKI-based therapies (2 patients; 3%), and 4 unknown cases. Outcomes by type of first-line therapy for de novo BP and in patients who progressed from CP/AP are shown in Supporting Information Figures 5A to 5D .
Factors Predictive of Survival Outcomes: Multivariate Analysis
We then created Cox regression models for OS (Table 4) and FFS (see Supporting Information Table 1 ) and identified factors that were associated with survival. In multivariate analysis (MVA) for OS, adjusting for different variables, age 58 years (hazard ratio [HR], 1.41; P 5 .004), platelet count 102 K/mL (HR, 0.65; P 5 .001), treatment with a TKI before transformation to CML-BP (HR, 1.51; P 5 .004), LDH level 1227 IU/L (HR, 1.32; P 5 .01), myeloid immunophenotype (HR, 1.67; P<.001), chromosome 15 aberrations (HR, 2.20; P 5 .02), transformation from CML-CP/AP (vs de novo CML-BP: HR, 1.43; P 5 .06), and treatment with SCT after CML-BP (HR, 0.40; P<.001) were found to be significantly associated with OS. In a separate MVA, we noted that the achievement of MHR and/or CCyR emerged as the most significant independent predictors of survival whereas isolated EMD was no longer associated with survival (data not shown). Type of clonal evolution by group 1, group 2, both, or neither group did not appear to be predictive of OS.
We then analyzed FFS in patients for whom we had the available information for their frontline therapy for CML-BP (426 patients). The following factors were found to significantly predict for an increased risk of failure in MVA: myeloid immunophenotype, prior TKI therapy, presence of chromosome 3 aberrations, lack of SCT after CML-BP, non-TKI-based therapy, and a platelet count <102 K/mL (see Supporting Information Table 1 ). Similar to OS, the achievement of MHR and/or CCyR was predictive of a longer FFS, whereas isolated EMD did not predict for FFS after adjusting for response. In addition, receipt of a higher number of TKI therapies before progressing to CML-BP also was associated with inferior survival in MVA (P 5 .055 for OS and P 5 .019 for FFS).
DISCUSSION
Despite the marked progress in therapy for patients with CML, patients who transform to CML-BP have a dismal outcome, particularly if they have been previously treated with a TKI. To the best of our knowledge, this is the largest study to date describing the characteristics and outcomes of patients with CML-BP who are treated with a TKI. We have identified that myeloid immunophenotype, treatment with a TKI before transformation to CML-BP, age 58 years, LDH level 1227 IU/L, platelet count < 102 3 10 9 /L, no treatment with SCT after BP treatment, transformation to CML-BP from CP/AP, and the presence of chromosome 15 aberrations were predictive of poor survival in patients with CML-BP.
The incidence of CML-BP has markedly decreased after the introduction of TKIs for the treatment of CML, particularly with the use of second-generation and thirdgeneration inhibitors. 5, 13 However, the data from the current study suggest that although the outcome is poor, with a median survival of only 12 months, the survival has progressively improved over time. As shown in Figure 1D , there is an improvement in outcome after the introduction of a TKI and after 2005, when second-generation TKIs became increasingly available (first through clinical trials and later through standard of care), it has improved further. This potentially could be due to the increased use of TKIs combined with chemotherapy followed by SCT after the diagnosis of CML-BP.
9,14 The current study results are similar to those reported in previous smaller series of patients treated mostly with imatinib. 7, 15 This is despite more patients having received prior TKIs before transformation, an adverse prognostic factor identified in the current analysis. The current study data also suggest that treatment with dasatinib may confer a survival benefit when compared with treatment with imatinib. This is perhaps not unexpected considering the higher potency, wider coverage of ABL mutants, and the reported significant albeit modest success for patients treated with dasatinib after imatinib failure. 10 Although it would be expected that a similar benefit would be observed with other newer agents, the current study cohort included too few patients treated with each individual TKI to draw firm conclusions in this regard. Similarly, we were unable to make any inferences regarding the relative benefit of the different second-generation TKIs. One of the caveats of the current study data are that the study is retrospective and the treatment, kinase domain mutation data, and the response data were not available for all patients. Furthermore, in the current analysis, as therapy became more effective, the rate of transformation decreased over time. For example, only 36 patients were diagnosed with CML-BP after 2013. This affected the exposure to newer TKIs such as ponatinib, which was approved in December 2012. Only 8 of these 36 patients were treated with a ponatinib-based regimen as a first-line therapy for CML-BP (including both patients with documented T315I) because combination therapies with other TKIs were better known and preferred over a single-agent TKI by that time. Eventually, 2 additional patients received ponatinib for CML-BP as this therapy and combinations based on ponatinib became more established. 16 We further identified that the use of non-TKI-based therapies was independently predictive of poor FFS compared with TKI-based treatments. In the current analysis, the median time from the initial diagnosis of CML-CP to BP was 41 months (range, 0.7-298 months), which is perhaps longer than would be expected. The precise reasons for these longerthan-expected times to transformation are not clear, but we hypothesize that the availability of TKIs and other treatment options, many of them in clinical trials before they were widely available, allowed patients to remain in CP longer even if not achieving an optimal response.
To our knowledge, the pathogenesis of CML-BP in the TKI era has received little attention, 17 and precise molecular mechanisms/mutational/epigenetic changes delineating the transition from CML in CP to AP and CML-BP still are unclear. It is possible that treatment with a TKI exerts a selection pressure over CML cells, which can then evolve over time and develop into an overt BP. 18 The data from the current study could be viewed as supportive of this hypothesis because we have demonstrated that prior TKI therapy was a poor prognostic factor in patients with CML-BP. Whether this transition depends on exposure to a TKI or is secondary to an inherent mutation profile of various subclones that evolve over time is unclear. 19 The existence of these subclones, which could predispose to an overt BP, is supported by one study that demonstrated that the presence of cells with aberrant immunophenotype (myeloid or lymphoid) in patients with CML-CP can predispose them to CML-BP. 20 To our knowledge, the question of whether the subclones give rise to a more resistant disease is not known, but because we have demonstrated that patients with de novo CML-BP had better outcomes compared with patients whose CML transformed from CP/AP (see Supporting Information Fig. 5 ), the current study results would be compatible with this hypothesis. The results of the current study also demonstrate a very high incidence of clonal evolution, which is more frequently observed than ABL kinase domain mutations, suggesting that transformation is the result of complex molecular processes rather than the mere development of resistance to a TKI. One recent study suggested the presence of novel fusions in the MLL gene and in the ANKRD11 gene in patients with CML-BP, using RNA sequencing. 21 Previously, ABL, RUNX1, ASXL1, 22 and IDH1 mutations were described in patients with CML-BP 23 ; however, paired sample analysis from several patients receiving TKI therapy was not reported. In contrast, the presence and type of ABL kinase domain mutations were found to have minimal prognostic consequences, as we had previously reported. 24 The current analysis generated some novel findings. We identified that chromosome 15 aberrations, which are uncommon in patients with CML, constitute a poor prognostic risk factor in patients with CML-BP. Chromosome 15 abnormalities are identified as a minor route abnormality in patients with CML. 25 The long arm of chromosome 15 contains a tumor suppressor gene, CCNDBP1, 26 that is downregulated in different cancers, but to our knowledge its role in CML is unknown. In addition, we identified the optimal cutoff points for various parameters that indicated high disease burden in patients with CML-BP such as elevated serum LDH levels, a low platelet count, and a low hemoglobin level. Advanced age and low hemoglobin were shown to be predictive of poor survival in another study of 51 patients with CML-BP, the majority of whom were not treated with a TKI.
2 Some chromosomal abnormalities were found to be significantly correlated to survival in univariate analysis but not MVA, such as trisomy 8 and trisomy 19. It is interesting to note that the type of clonal evolution 12 and chromosome 17 abnormalities were not found to be predictive of survival. In addition, age 58 years and a lack of SCT after the diagnosis of BP also were found to be predictive of poor OS. The results of the current study also demonstrated that prognostic factors for FFS were similar to those for OS, except that non-TKI-based therapy and chromosome 3 aberrations significantly predicted for an increased risk of failure of first-line therapy. Chromosome 3 aberrations previously were reported to have a poor prognostic impact in patients with CML. 27 It is important to note that response to therapy is incorporated into the MVA: the achievement of MHR or CCyR after first-line treatment of CML-BP was found to be a stronger predictor of longer survival compared with other prognostic factors. We also identified isolated EMD as a favorable factor for survival compared with those patients with bone marrow involvement with or without EMD.
To our knowledge, the results of the current study provide the most comprehensive analysis presented to date of the disease characteristics and outcomes of patients with CML-BP in the TKI era. It identifies novel leads into the prognostication and survival outcomes of patients with CML-BP in the TKI era. Treatment with a combination of TKIs and chemotherapy followed by SCT remains the backbone of treatment in these patients. New approaches to treat patients with CML-BP that address the molecular complexity of CML-BP are needed.
